ETST · Earth Science Tech, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $35.96M | $35.7M | $33.12M | $11.95M | $48.54K | $14.12K | $140.9K | $526.14K | $770.64K | $463.11K | $80.28K | $7450 | $41.89K | $22.42K | |
| — | — | -$21.19K | -$67.21K | -$47.43K | — | — | — | — | — | — | — | — | — | |
| $10.29M | $10.21M | $8.82M | $4.13M | $26.48K | $22.64K | $100.97K | $307.67K | $475.62K | $270.22K | $77.06K | $900 | $6762 | $3600 | |
| $25.67M | $25.49M | $24.3M | $7.83M | $22.06K | -$8516 | $39.93K | $218.47K | $295.01K | $192.89K | $3219 | $6550 | $35.13K | $18.82K | |
| — | 71.4% | 73.38% | 65.49% | 45.45% | -60.3% | 28.34% | 41.52% | 38.28% | 41.65% | 4.01% | 87.92% | 83.86% | 83.94% | |
| — | — | — | — | $0 | $0 | $9000 | $76.11K | $338.86K | $150.45K | $32.59K | — | — | — | |
| — | — | — | — | $8074 | $3655 | — | — | — | — | — | — | — | — | |
| — | — | — | — | $231.89K | $116.06K | $228.79K | $551.48K | $514.47K | $653.24K | $115.11K | $6856 | — | — | |
| $3.64M | $3.57M | $4.15M | $166.98K | $231.89K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | $13.83K | — | — | — | $4406 | $4406 | — | — | — | — | |
| $316.69K | $284.4K | $151.65K | $149.75K | $17.49K | — | $2421 | $7229 | $11.53K | $23.53K | $4481 | — | — | — | |
| $22.03M | $22.18M | $20.85M | $6.94M | $958.74K | $218.19K | $4.34M | $1.13M | $2.43M | $1.9M | $8.77M | $12.55M | $96.63K | $41.6K | |
| — | — | — | $892.35K | -$936.68K | -$226.71K | -$4.3M | -$908.57K | -$2.14M | -$1.71M | -$8.77M | -$12.54M | -$61.5K | -$22.78K | |
| — | — | — | 7.47% | -1929.83% | -1605.23% | -3053.27% | -172.69% | -277.66% | -369% | -10919.58% | -168318.35% | -146.83% | -101.58% | |
| — | — | — | $1.04M | -$919.19K | — | -$4.3M | -$901.34K | -$2.13M | -$1.69M | -$8.76M | — | — | — | |
| $28.25K | $16.33K | $21.19K | $67.21K | $47.43K | $86.71K | $4765 | $4765 | $75.63K | $4765 | $4730 | — | — | — | |
| — | $67.19K | — | -$67.21K | $571.28K | $3.4M | -$81.06K | -$291.69K | -$75.63K | -$4765 | — | — | — | — | |
| $3.59M | $3.09M | $3.37M | $825.14K | -$365.41K | $3.17M | -$4.38M | -$1.2M | -$2.22M | -$1.71M | -$8.77M | -$12.54M | — | — | |
| — | -$511.68K | $116.78K | $13K | — | — | — | — | — | — | — | — | $0 | $0 | |
| $3.89M | $3.63M | $3.25M | $812.14K | -$365.41K | $3.17M | -$4.38M | -$1.2M | -$2.22M | -$1.71M | -$8.77M | -$12.54M | -$62.03K | -$22.85K | |
| — | 10.17% | 9.82% | 6.79% | -752.84% | 22468.74% | -3110.8% | -228.12% | -287.47% | -370.03% | -10925.32% | -168319.77% | -148.08% | -101.92% | |
| -$30.01K | -$29.84K | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | $0.01 | $0.01 | $0.01 | $0.00 | -$0.00 | $0.06 | -$0.08 | — | — | — | — | — | — | — |
| USD/shares | $0.01 | $0.01 | $0.01 | $0.00 | -$0.00 | — | — | — | — | — | — | — | — | — |
| shares | — | 293.07M | 303.52M | 309.69M | 145.87M | 53.85M | — | — | — | — | 36.84M | 10.76M | 9.49M | 6.7M |
| shares | — | 293.07M | 303.52M | 309.69M | 145.87M | — | — | — | — | — | 36.84M | 10.76M | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2026: $2.12M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 38 similar-size Drug Manufacturers - Specialty & Generic companies (of 97 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2026 | FY2025 |
|---|---|---|
| Sale of Pharmaceutical Products and Medical Consultations | $32,908,881 | $30,027,373 |
| Shipping And Handling | $2,485,908 | $3,090,251 |
| Other Revenue | $300,825 | — |